110 related articles for article (PubMed ID: 6666223)
41. Plasma concentrations of isosorbide dinitrate and mononitrates after acute and chronic oral administration of isosorbide dinitrate in man.
Bruyneel K; Rosseel MT; Bogaert MG
Arzneimittelforschung; 1982; 32(7):769-73. PubMed ID: 6889879
[TBL] [Abstract][Full Text] [Related]
42. [The evaluation of the bioavailability of isosorbide 5-mononitrate].
Dyderski S; Szkutnik D; Drobnik L; Szymańska-Shawkat E
Pol Merkur Lekarski; 1999 Aug; 7(38):64-6. PubMed ID: 10522420
[TBL] [Abstract][Full Text] [Related]
43. [Pharmacokinetics and bioavailability of a new slow-release isosorbide-5-mononitrate system].
Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
Cardiologia; 1987 Nov; 32(11):1287-91. PubMed ID: 3447701
[No Abstract] [Full Text] [Related]
44. Pharmacokinetics of various preparations of organic nitrates.
Kampmann JP
Drugs; 1987; 33 Suppl 4():5-8. PubMed ID: 3113910
[TBL] [Abstract][Full Text] [Related]
45. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
Assinder DF; Chasseaud LF; Taylor T
J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
[TBL] [Abstract][Full Text] [Related]
46. [Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate].
Heidemann R; Gracien E; Menke G; Rietbrock N
Dtsch Med Wochenschr; 1987 May; 112(18):719-22. PubMed ID: 3569063
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.
Steudel HC; Volkenandt M; Steudel AT
Z Kardiol; 1983; 72 Suppl 3():24-8. PubMed ID: 6666228
[TBL] [Abstract][Full Text] [Related]
48. [Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat].
Leitold M; Laufen H
Arzneimittelforschung; 1983; 33(8):1117-21. PubMed ID: 6685489
[TBL] [Abstract][Full Text] [Related]
49. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
Johnson KI; Gladigau V; Schnelle K
Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234
[TBL] [Abstract][Full Text] [Related]
50. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF
Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of nitroglycerin and long-acting nitrate esters.
Fung HL
Am J Med; 1983 Jun; 74(6B):13-20. PubMed ID: 6407312
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
Sponer G; Kühnle HF; Strein K; Bartsch W; Endele R; Dietmann K
J Pharmacol Exp Ther; 1984 Jan; 228(1):235-9. PubMed ID: 6694105
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis.
Evers J; Bonn R; Boertz A; Cawello W; Luckow V; Fey M; Aboudan F; Dickmans HA
Eur J Clin Pharmacol; 1987; 32(5):503-5. PubMed ID: 3622599
[TBL] [Abstract][Full Text] [Related]
54. Isosorbide dinitrate pharmacokinetics.
Taylor T; Chasseaud LF; Doyle E; Bonn R; Darragh A; Lambe RF
Arzneimittelforschung; 1982; 32(10):1329-33. PubMed ID: 6891236
[No Abstract] [Full Text] [Related]
55. Influence of standard and nicotine-reduced cigarette smoke on plasma concentrations of isosorbide dinitrate and its metabolites in rats.
Gomita Y; Furuno K; Araki Y
J Pharm Pharmacol; 1991 Nov; 43(11):811-2. PubMed ID: 1686914
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon.
Doyle E; Chasseaud LF
J Pharm Sci; 1981 Nov; 70(11):1270-2. PubMed ID: 7299675
[TBL] [Abstract][Full Text] [Related]
57. Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers.
Sawicki W; Deptulski T; Janicki S
Pharmazie; 1989 Apr; 44(4):280-1. PubMed ID: 2772003
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of isosorbide-5-nitrate in renal failure.
Evers J; Krakamp B; Klimkait W; Dickmans HA; Maddock J; Luckow V; Cawello W; Weiss M
Eur J Clin Pharmacol; 1986; 30(3):349-50. PubMed ID: 3732374
[TBL] [Abstract][Full Text] [Related]
59. [Pharmacokinetics of isosorbide-5-mononitrate in patients with advanced renal failure].
Kösters W; Klotschkoff P; Abshagen U
Med Welt; 1981 Apr; 32(14A):521-3. PubMed ID: 7242312
[No Abstract] [Full Text] [Related]
60. Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys.
Pressmar F; Neidlein R; Strein K; Bartsch W
Arzneimittelforschung; 1992 Oct; 42(10):1186-91. PubMed ID: 1472139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
